77-38-3
Chemical Structure
Chlorphenoxamine
- CAS No.: 77-38-3
- Formula:C18H22ClNO
- Molecular Weight:303.83
IUPAC Name: 2-(1-(4-chlorophenyl)-1-phenylethoxy)-N,N-dimethylethan-1-amine
InChIKey: KKHPNPMTPORSQE-UHFFFAOYSA-N
SMILES: CN(CCOC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)C)C
Biological Activity: Chlorphenoxamine, an antihistamine and anticholinergic agent is a GPCR antagonist. Chlorphenoxamine inhibits multiple lethal viral diseases, such as SARS-CoV, MERS-CoV, EBOV and malaria. Chlorphenoxamine shows anti-filovirus activity against both EBOV and Marburg virus (MARV) with IC50s of 1.1 μM and 6.2 μM, respectively. Chlorphenoxamine is used for allergic conditions, urticaria, viral diseases and Parkinson’s disease[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Chlorphenoxamine | 99.20% | Chlorphenoxamine, an antihistamine and anticholinergic agent is a GPCR antagonist. Chlorphenoxamine inhibits multiple lethal viral diseases, such as SARS-CoV, MERS-CoV, EBOV and malaria. Chlorphenoxamine shows anti-filovirus activity against both EBOV and Marburg virus (MARV) with IC50s of 1.1 μM and 6.2 μM, respectively. Chlorphenoxamine is used for allergic conditions, urticaria, viral diseases and Parkinson’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chlorphenoxamine (Standard) | ≥98% | Chlorphenoxamine (Standard) is the analytical standard of Chlorphenoxamine (HY-B1607). This product is intended for research and analytical applications. Chlorphenoxamine, an antihistamine and anticholinergic agent is a GPCR antagonist. Chlorphenoxamine inhibits multiple lethal viral diseases, such as SARS-CoV, MERS-CoV, EBOV and malaria. Chlorphenoxamine shows anti-filovirus activity against both EBOV and Marburg virus (MARV) with IC50s of 1.1 μM and 6.2 μM, respectively. Chlorphenoxamine is used for allergic conditions, urticaria, viral diseases and Parkinson’s disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ashraf A, et al. Novel RP-HPLC-DAD approach for simultaneous determination of chlorphenoxamine hydrochloride and caffeine with their related substances. BMC Chem. 2024;18(1):133. Published 2024 Jul 19. [Content Brief]
- [2]. Ashraf A, et al. Smart green spectrophotometric estimation and content uniformity testing of chlorphenoxamine HCl and caffeine in bulk forms and combined pharmaceutical formulation. Sci Rep. 2025;15(1):9482. Published 2025 Mar 19. [Content Brief]
- [3]. BAZEX A, et al. Trial treatment of urticaria with chlorphenoxamine. Clinique (Paris). 1963 Jul-Aug;58:447-50. [Content Brief]
- [4]. ULDALL PR, et al. Chlorphenoxamine hydrochloride in parkinsonism. A controlled trial. Br Med J. 1961 Jun 10;1(5240):1649-52. [Content Brief]
- [5]. Schafer A, et al. Repurposing potential of 1st generation H1-specific antihistamines as anti-filovirus therapeutics. Antiviral Res. 2018 Sep;157:47-56. [Content Brief]
